NCT02723591View on ClinicalTrials.gov

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

599

Participants

Timeline

Start Date

September 9, 2016

Primary Completion Date

June 14, 2019

Study Completion Date

June 14, 2019

Conditions
Kidney Transplantation
Interventions
DRUG

Tacrolimus

Oral Capsule

DRUG

Tacrolimus immediate release

Oral Capsule

Trial Locations (30)

10032

Site US10037, New York

10065

Site US10022, New York

10467

Site US10028, New York

13210

Site US10021, Syracuse

14215

Site US10004, Buffalo

20007

Site US10014, Washington D.C.

21201

Site US10001, Baltimore

22042

Site US10008, Falls Church

22903

Site US10012, Charlottesville

29425

Site US10002, Charleston

32224

Site US10030, Jacksonville

35294

Site US10006, Birmingham

48109

Site US10013, Ann Arbor

48202

Site US10032, Detroit

53792

Site US10023, Madison

55455

Site US10029, Minneapolis

55905

Site US10027, Rochester

60605

Site US10020, Chicago

60611

Site US10010, Chicago

77030

Site US10036, Houston

80045

Site US10024, Aurora

84112

Site US10018, Salt Lake City

85259

Site US10025, Scottsdale

90033

Site US10031, Los Angeles

94115

Site US10016, San Francisco

95817

Site US10005, Sacramento

97210

Site US10026, Portland

06510

Site US10003, New Haven

02114

Site US10007, Boston

07039

Site US10019, Livingston

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02723591 - To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter